News

Objective responses were reported for two patients, and stable disease was observed in 22 patients. The trail was the first reported human study of an antibody to trail

Financial Results Total revenue for the first nine months of fiscal 2009 was CAD4.8 million against CAD5.5 million for the first nine months of fiscal 2008. The majority

Under the agreement, Janssen may select up to 12 programs from Galapagos’s internally identified rheumatoid arthritis (RA) targets into the alliance. Janssen receives future option rights to exclusively

Out of the 18 patients enrolled, five achieved stable disease lasting greater than three months. Data from the study demonstrates that Panzem NCD (2ME2 or 2-methoxyestradiol), administered as

To date, 60 patients have been enrolled in the Phase I trial with ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase. No dose-limiting toxicity

Ostene is the only available product designed to stop bone bleeding in surgery that does not interfere with bone healing or increase the risk of surgical infections, including

The reduction in Ca125 biomarker provides an early sign that a treatment regimen is effective in combating ovarian cancer. At the reported doses, toxic effects observed were generally

Twice-daily delivery of nebulized formoterol fumarate was well tolerated over a 12-month treatment period in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Perforomist inhalation solution is the

ARRY-543, a small molecule that is administered orally, was well-tolerated up to 300 mg BID (twice daily). The maximally tolerated dose has not yet been established on the